-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

Benzinga·03/23/2026 16:51:26
Listen to the news
Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $10 to $12.